Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Not applicable

A Clinical Study to Evaluate the Effects of a Supplement on Cognitive Function

NCT07883525 · tracked via the Priya Life Science USA tracker
Sponsor
Necternal LLC
Phase
Not applicable
Started
2026-08-01
Last updated
2026-10-20

Condition(s) studied

Cognition ImprovementCognition Function

Investigational drug(s) / intervention(s)

Necternal SupplementPlacebo

Necternal Supplement: All participants will be using the test product as directed. Participants will take 2 stick packs daily, one in the morning and one evening, with 16 oz of water

Placebo: Arm 2 will take a placebo product for the duration of the trial.

Study summary

This is a virtual, two-armed, randomized, triple-blinded, placebo-controlled clinical trial that will last 16 weeks.

Participants will take the supplement or a placebo product twice daily and complete questionnaires at Baseline, 2 weeks, 6 weeks, 12 weeks, and 16 weeks.

Participants will complete cognitive assessments at Baseline, 4 weeks, 8 weeks, and 16 weeks.

Eligibility

Sex
ALL
Min age
21 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Be male or female. * Be aged 21-65. * Anyone currently experiencing issues regarding at least three of the following: * Brain fog (e.g. slowed thinking, forgetfulness, difficulty articulating thoughts, etc.) * Difficulty concentrating or focusing for periods longer than 20 minutes * Difficulty learning and retaining new information * Poor mental clarity * Difficulties with memory (e.g. names, locations, what your are doing, etc.) * Low energy (i.e. inability to complete daily tasks without feeling significantly fatigued or tired) * Frequent irritability or mood swings (i.e. 2-3 times per week or more) * Difficulties remaining calm or a frequently feeling worried or anxious * If taking other supplements, prescription medications, or herbal remedies that target cognitive abilities, energy levels, or mood and well-being, has been doing so consistently for at least three months, and is willing to maintain this routine for the study duration. * Agrees to avoid introducing any other new product, supplements, or herbal remedies for the duration of the study. * Willing to maintain their current diet, sleep schedule, and activity level for the duration of the study. * Resides in the United States. Exclusion Criteria: * Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders. * History of neurodegenerative disease (e.g., Alzheimer's, Parkinson's), history of traumatic brain injury (including concussions), stroke, epilepsy, or uncontrolled migraine. * History of diagnosed mood disorders, such as depression, bipolar disorder, or seasonal affective disorder. * History of sleep disorders, such as insomnia, narcolepsy, or sleep apnea. * Anyone with any allergies or sensitivities to any of the study product ingredients. * Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period). * Anyone unwilling to follow the study protocol. * Currently partaking in another research study or will be partaking in any other research study at any point during this study's duration.

Primary outcome measure(s)

  • Change in Cognitive Function as Assessed by Polygons — Baseline, 4 weeks, 8 weeks, and 16 weeks
    Mean change from baseline in the Polygons test score, assessing processing speed and judgment. Participants will complete a timed, computerized cognitive assessment with a duration of 1 minute and 30 seconds. The outcome will be calculated as the mean change in test score from baseline at each follow-up assessment.
  • Change in Cognitive Function as Assessed by Double Trouble — Baseline, Week 4, Week 8, and Week 16
    Mean change from baseline in the Double Trouble test score, assessing selective attention and processing speed. Participants will complete a timed, computerized Stroop-based cognitive assessment with a duration of 1 minute and 30 seconds. The outcome will be calculated as the mean change in test score from baseline at each follow-up assessment.
  • Change in Cognitive Function as Assessed by Feature Match — Baseline, Week 4, Week 8, and Week 16
    Mean change from baseline in the Feature Match test score, assessing focus and processing. Participants will complete a timed, computerized cognitive assessment with a duration of 1 minute and 30 seconds. The outcome will be calculated as the mean change in test score from baseline at each follow-up assessment.

Trial sites (1)

FacilityCityRegionStatus
Citruslabs Las Vegas Nevada
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07883525 on ClinicalTrials.gov ↗ ← All trials in the USA